Update Your ProfileAcademic Title:
Faculty Member
Primary Appointment:
Radiation Oncology
Additional Title:
Clinical Associate Professor, Department of Radiation Oncology
Email:
Location:
Central Maryland Radiation Oncology 10710 Charter Drive G030 Columbia, MD 21044
Phone (Primary):
443-546-1300
Fax:
410-740-9301
Education and Training
• MD, Georgetown University School of Medicine (2007)
• BS, Chemistry, University of California, Berkeley (1996)
• BA, Molecular and Cell Biology (Neurobiology emphasis), University of California, Berkeley (1996)
• Internship, Internal Medicine, Georgetown University Hospital (2007–2008)
• Residency, Radiation Oncology, National Cancer Institute, NIH/National Capital Consortium (2008–2012)
• Chief Resident (2011–2012)
Biosketch
Dr. Meredith Hope Wernick brings over a decade of experience in clinical radiation oncology, translational research, and patient-centered cancer care. Dr. Wernick has expertise in treating a broad spectrum of malignancies with advanced radiation modalities, including intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), stereotactic radiosurgery (SRS), stereotactic body radiation therapy (SBRT), and brachytherapy. She also has extensive experience in quality improvement initiatives and has served as the Chair of the Quality Improvement Committee at her institution’s cancer center.
Dr. Wernick is a Board Member of the Maryland and District of Columbia Society of Clinical Oncology (MDCSCO), where she actively contributes to advancing cancer care through advocacy, education, and policy initiatives.
Dr. Wernick is committed to advancing precision oncology through innovative research and patient advocacy, ensuring that every patient receives personalized and comprehensive cancer care.
Research/Clinical Keywords
Cancer
Highlighted Publications
1. Russo AL, Jedlicka K, Wernick M, et al. Urine analysis and protein networking identify MET as a marker of metastatic prostate cancer. Cancer Research. 2009; 69(13):4292-8. PMID: 19549766.
2. Anand N, Murthy S, Amann G, Wernick M, et al. Protein elongation factor EEF1A2 is a putative oncogene in ovarian cancer. Nature Genetics. 2002; 31(3):301-5. PMID: 12053177.
3. Hodgson G, Hager JH, Volik S, Wernick M, et al. Genome scanning with array CGH delineates regional alterations in mouse islet carcinomas. Nature Genetics. 2001; 29(4):459-64. PMID: 11694878.
4. Thakur M, Wernick M, Collins C, et al. DNA polymerase eta undergoes alternative splicing, protects against UV sensitivity and apoptosis, and suppresses Mre11-dependent recombination. Genes, Chromosomes & Cancer. 2001; 32(3):222-35. PMID: 11579462.
5. Collins C, Volik S, Kowbel D, Wernick M, et al. Comprehensive genome sequence analysis of a breast cancer amplicon. Genome Research. 2001; 11(6):1034-42. PMID: 11381030.
Research Interests
Dr. Wernick has an extensive background in molecular oncology research, including work in early cancer detection, biomarker discovery, and the molecular mechanisms underlying radiation response. Her research at the National Cancer Institute focused on microRNA regulation in response to ionizing radiation and the development of non-invasive biomarkers for cancer diagnosis. Prior to her medical training, she worked in biotech and academic research settings, including UCSF Comprehensive Cancer Center, Lawrence Berkeley National Laboratory, and Sigma-Aldrich Corporation, where she contributed to the development of genomic and proteomic tools for cancer research.
Research Interests
• Biomarkers and molecular mechanisms of radiation response
• Genomic and proteomic profiling for cancer diagnosis and treatment stratification
• Personalized approaches to radiation therapy
• Cancer survivorship and patient navigation in oncology care
Awards and Affiliations
• Commander’s Award for Public Service
• Hammerman Scholarship, Georgetown University School of Medicine
• J. Grossmith Scholarship, University of California, Berkeley
• Charles Fish Scholarship, University of California, Berkeley